The aim of the fixed-duration approach is to "produce deep remissions and thereby allow patients to get off therapy while ...

SAN DIEGO — Treatment with the oral Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib in combination with venetoclax was associated with improved progression-free survival compared with ...

Medical experts illustrate the impact of combination therapy for treatment of CLL and SLL. This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Tara ...

Acalabrutinib demonstrates a favorable cardiovascular safety profile in CLL, with low cardiac failure rates compared to ibrutinib and chemoimmunotherapy. The selectivity of acalabrutinib reduces ...

Matching adjusted indirect comparison addresses key questions and limitations associated with previously presented analysis and suggests efficacy advantage of BRUKINSA vs acalabrutinib In this MAIC, ...

Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed ...

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA The rates of complete ...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to ...

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Jaypirca (pirobrutinib) for the treatment of ...